Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Total Enrollment
39 participants
Study Classification
OBSERVATIONAL
Study Start Date
2023-12-01
Study Completion Date
2027-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this observational cohort study is to investigate the effect of intense pulsed light (IPL) for excessive hair in patients \>18 years of age and in need of gender affirmative treatment, refered to the department of dermatology and venereology, Umeå University Hospital, Sweden. The main questions this study aims to answer are:
* \[To evaluate the effect of consecutive IPL treatments in women with hirsutism due to polycystic ovarial syndrome (PCOS), with or without anti-androgen treatment\]
* \[To evaluate the effect of consecutive IPL treatments in individuals born as biologically men but in transition to become women, with or without hormonal treatment\].
Patients will use self-assessed questionnaires evaluating:
* Background characteristics and time spend on concealing, reducing and treating hypertrichosis at home.
* Ferriman-Gallwey scale, regarding the intensity of their hypertrichosis.
* Dermatology Life Quality Index (DLQI) for quality of life Patients will be recruited consecutively and assessed at each visit, at the clinic before the treatments, ranging from baseline to a minimum of 5 treatment sessions.Since this is an observational study, all patients are treated by others than the researchers according to the routines och the clonic and there will be no other groups to compare the patients with.
* \[To evaluate the effect of consecutive IPL treatments in women with hirsutism due to polycystic ovarial syndrome (PCOS), with or without anti-androgen treatment\]
* \[To evaluate the effect of consecutive IPL treatments in individuals born as biologically men but in transition to become women, with or without hormonal treatment\].
Patients will use self-assessed questionnaires evaluating:
* Background characteristics and time spend on concealing, reducing and treating hypertrichosis at home.
* Ferriman-Gallwey scale, regarding the intensity of their hypertrichosis.
* Dermatology Life Quality Index (DLQI) for quality of life Patients will be recruited consecutively and assessed at each visit, at the clinic before the treatments, ranging from baseline to a minimum of 5 treatment sessions.Since this is an observational study, all patients are treated by others than the researchers according to the routines och the clonic and there will be no other groups to compare the patients with.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa
NCT03203122
Hidradenitis Suppurativa
Acne Inversa
UNKNOWN
NA
Clinical Investigation of Safety and Effectiveness of Emerald IPLdevice
NCT03945383
Hair Removal
COMPLETED
NA
To Comapre The Effectiveness of Two Lasers in The Treamment of Unwanted Hair
NCT05739799
Hirsuitism
COMPLETED
NA
Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser
NCT03054155
Hidradenitis Suppurativa
COMPLETED
NA
Magic Shave Powder Gold's Affects on the Occurrence of Pseudofolliculitis Barbae
NCT04220502
Pseudofolliculitis Barbae
WITHDRAWN
EARLY_PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background Hypertrichosis is defined as excessive hair in men and women while the term hirsutism is used for women with increased hair count due to hormonal changes such as increased levels of androgens. Hypertrichosis can be focal och general and hereditary or acquired. In hereditary hypertrichosis, genes or in uterus exposure to certain medications have been suggested as causes for the condition. In acquired cases, the hypertrichosis is often triggered by hormonal changes due to different medical conditions.
Investigating the cause of hypertrichosis is done by examining the patient's medical history and a complete examination of the skin. An often-used tool, for severity assessment of hypertrichosis is Ferriman \& Gallwey scale. This international scale is used both by clinicians and patients for both research and in clinical practice. The Ferriman \& Gallwey scale investigate 9 parts of the body with each part visually described with increasing density of hair as 4 pictures ranging from 0 point (no hair) to 4 points (dense hair). According to Ferriman \& Gallwey scale, a total of ≥8 points in white and black, ≥9-10 points for mediterranean, south american and middle eastern, and ≥2 points for east Asian women indicate hypertrichosis.
Hirsutism is a common feature in women with Polycystic Ovarian Syndrome. The increased density of hair becomes noticeable during puberty and affected women report a great negative impact from the condition on their quality of life. Signs of depression and anxiety are common in women with hirsutism, due to increased social isolation and remarks regarding the hair growth and its colour by their surroundings.
Individuals with gender dysphoria and in transition of gender reassignment from the biological male sex to female, are sometimes prescribed estrogen or anti-androgens to decrease male characteristics on their body. Feminizing hormone therapy for male-to-female gender dysphoria aim to minimize body and facial hair growth. In women with mild hirsutism, there is evidence that oral contraceptives and anti-androgen treatment could be beneficial against hair growth on the body. However, the effects of these medications together with other methods such light-based treatments as intense pulsed light or lasers have not been evaluated. Intense Pulsed Light (IPL) which transmit light as energy to become absorbed as heat in the hair follicle. Repeated treatments are necessary to obtain a significant reduction of hair and long-term effects of IPL in reducing hair varies. Theoretically, the combination of anti-androgens and estrogen together with IPL, should have a synergetic effect in hair reduction no matter the intention for hair reduction. Thus, the aim of this study is to evaluate the effects of IPL, in patient with hirsutism/hypertrichosis, with or without hormonal therapy, regarding hair reduction and potential impacts on quality of life.
Materials and methods Study design Observational Cohort study Patients Patients with hirsutism and gender dysphoria are medically treated and have their follow-ups by other specialities than dermatology. However, the laser clinic at the department of dermatology and venereology, Umeå university hospital receives referrals from other departments across northern Sweden for reducing body hair in these patients. Consecutive patients referred to the department of dermatology and venereology at Umeå University Hospital due to hypertrichosis will be assessed according to our inclusion and exclusion criteria.
Inclusion criteria:18 years of age and above, diagnosis of PCOS obtained by a gynaecologist and hirsutism, diagnosis of gender dysphoria obtained after psychiatric evaluation, ≥3 points in hair density according to Ferriman-Gallwey scale on a specific part of the body. Exclusion criteria: Language barrier causing problem in understanding questionnaires or not being able to give consent, hair colours of white, orange or grey hair, skin type 5 and above according to Fitzpatrick and hereditary hypertrichosis.
Data collection The procedure of hair reduction by light based methods are done primarily by nurses and it is only in case of complications a physician is advised. Data will be collected by a coded, pre-treatment hypertrichosis specific questionnaire, asking about participants background, medical history, current medication, subjective assessment of hair density according to Visual Analogue Scale (VAS-10 point scale), localisation of hypertrichosis, Ferriman-Gallwey scale and Dermatology Life Quality Index (DLQI). DLQI is a health questionnaire for dermatology consisting of 10 questions. DLQI investigates quality of life, the duration of one week back in time. A total of 0-30 points can be yielded from the questionnaire and the more points gained, is interpreted as more negative impacts on quality of life. At each follow-up (3 months interval) the participants will be asked to fill in the questionnaire and data from a total of 5 follow-ups will be collected. All patients will be treated by nurses at the clinic, with IPL (Intense pulsed light) Nordlys by Ellipse, using a 645- to 950-nm cut off filter. Data regarding dose, wavelength and number of pulses given at each treatment session will be collected. This data is recorded and saved inside the IPL machine.
Ethical considerations All patients will be asked for their oral and written consent after receiving information about the research project. Permissions regarding questionnaires used in this study will be obtained prior to the start of the study. An ethical permission to conduct this study will be obtained from the Swedish Ethical Review Board. As this is an observational study, none of the patients will receive any other treatment than they would have for hypertrichosis, at our clinic. Participating in this study does not mean extra visits nor any conveniences for the patients other than filling out coded questionnaires at the beginning of each treatment session. The researchers in this study will not treat any of the patients. All collected data is compiled and analysed at a group level. None of data or patient characteristics will be shared with other people outside the research group and all data will be saved electronically and kept inside in a locked room.
Statistics An estimate of 32 patients is required for the study to have a 80% chance of detecting, as significant at the 5% level, a decrease in the primary outcome measure (DLQI) from 10 points to 7 points. Considering 20% lost of response/inadequate filling of questionnaires will result in a total of 39 patients needed as sample size.
Background characteristics of patients and categorical variables will be tested with Chi-test. Normally distributed and continuous data, expressed as mean and standard deviation, will be tested for significant differences with pair t-test between the treatment sessions. Non continuous data, as median and inter quartile range will be subjected to non-parametric tests such as Mann-Whitney U test. Correlations will be tested by Pearson's correlation coefficient or spearman's rank test. Bivariate logistic regression model will be used to analyse probabilities of medications such as estrogen and anti-androgens as dependent variables, tested for outcome variables such as Ferriman-Galway scale and DLQI. International Business Machines Corporation (IBM), Statistical Package for the Social Sciences (SPSS) software will be used for statistics. A p-value less ≤ 0.05 is considered statistically significant.
Investigating the cause of hypertrichosis is done by examining the patient's medical history and a complete examination of the skin. An often-used tool, for severity assessment of hypertrichosis is Ferriman \& Gallwey scale. This international scale is used both by clinicians and patients for both research and in clinical practice. The Ferriman \& Gallwey scale investigate 9 parts of the body with each part visually described with increasing density of hair as 4 pictures ranging from 0 point (no hair) to 4 points (dense hair). According to Ferriman \& Gallwey scale, a total of ≥8 points in white and black, ≥9-10 points for mediterranean, south american and middle eastern, and ≥2 points for east Asian women indicate hypertrichosis.
Hirsutism is a common feature in women with Polycystic Ovarian Syndrome. The increased density of hair becomes noticeable during puberty and affected women report a great negative impact from the condition on their quality of life. Signs of depression and anxiety are common in women with hirsutism, due to increased social isolation and remarks regarding the hair growth and its colour by their surroundings.
Individuals with gender dysphoria and in transition of gender reassignment from the biological male sex to female, are sometimes prescribed estrogen or anti-androgens to decrease male characteristics on their body. Feminizing hormone therapy for male-to-female gender dysphoria aim to minimize body and facial hair growth. In women with mild hirsutism, there is evidence that oral contraceptives and anti-androgen treatment could be beneficial against hair growth on the body. However, the effects of these medications together with other methods such light-based treatments as intense pulsed light or lasers have not been evaluated. Intense Pulsed Light (IPL) which transmit light as energy to become absorbed as heat in the hair follicle. Repeated treatments are necessary to obtain a significant reduction of hair and long-term effects of IPL in reducing hair varies. Theoretically, the combination of anti-androgens and estrogen together with IPL, should have a synergetic effect in hair reduction no matter the intention for hair reduction. Thus, the aim of this study is to evaluate the effects of IPL, in patient with hirsutism/hypertrichosis, with or without hormonal therapy, regarding hair reduction and potential impacts on quality of life.
Materials and methods Study design Observational Cohort study Patients Patients with hirsutism and gender dysphoria are medically treated and have their follow-ups by other specialities than dermatology. However, the laser clinic at the department of dermatology and venereology, Umeå university hospital receives referrals from other departments across northern Sweden for reducing body hair in these patients. Consecutive patients referred to the department of dermatology and venereology at Umeå University Hospital due to hypertrichosis will be assessed according to our inclusion and exclusion criteria.
Inclusion criteria:18 years of age and above, diagnosis of PCOS obtained by a gynaecologist and hirsutism, diagnosis of gender dysphoria obtained after psychiatric evaluation, ≥3 points in hair density according to Ferriman-Gallwey scale on a specific part of the body. Exclusion criteria: Language barrier causing problem in understanding questionnaires or not being able to give consent, hair colours of white, orange or grey hair, skin type 5 and above according to Fitzpatrick and hereditary hypertrichosis.
Data collection The procedure of hair reduction by light based methods are done primarily by nurses and it is only in case of complications a physician is advised. Data will be collected by a coded, pre-treatment hypertrichosis specific questionnaire, asking about participants background, medical history, current medication, subjective assessment of hair density according to Visual Analogue Scale (VAS-10 point scale), localisation of hypertrichosis, Ferriman-Gallwey scale and Dermatology Life Quality Index (DLQI). DLQI is a health questionnaire for dermatology consisting of 10 questions. DLQI investigates quality of life, the duration of one week back in time. A total of 0-30 points can be yielded from the questionnaire and the more points gained, is interpreted as more negative impacts on quality of life. At each follow-up (3 months interval) the participants will be asked to fill in the questionnaire and data from a total of 5 follow-ups will be collected. All patients will be treated by nurses at the clinic, with IPL (Intense pulsed light) Nordlys by Ellipse, using a 645- to 950-nm cut off filter. Data regarding dose, wavelength and number of pulses given at each treatment session will be collected. This data is recorded and saved inside the IPL machine.
Ethical considerations All patients will be asked for their oral and written consent after receiving information about the research project. Permissions regarding questionnaires used in this study will be obtained prior to the start of the study. An ethical permission to conduct this study will be obtained from the Swedish Ethical Review Board. As this is an observational study, none of the patients will receive any other treatment than they would have for hypertrichosis, at our clinic. Participating in this study does not mean extra visits nor any conveniences for the patients other than filling out coded questionnaires at the beginning of each treatment session. The researchers in this study will not treat any of the patients. All collected data is compiled and analysed at a group level. None of data or patient characteristics will be shared with other people outside the research group and all data will be saved electronically and kept inside in a locked room.
Statistics An estimate of 32 patients is required for the study to have a 80% chance of detecting, as significant at the 5% level, a decrease in the primary outcome measure (DLQI) from 10 points to 7 points. Considering 20% lost of response/inadequate filling of questionnaires will result in a total of 39 patients needed as sample size.
Background characteristics of patients and categorical variables will be tested with Chi-test. Normally distributed and continuous data, expressed as mean and standard deviation, will be tested for significant differences with pair t-test between the treatment sessions. Non continuous data, as median and inter quartile range will be subjected to non-parametric tests such as Mann-Whitney U test. Correlations will be tested by Pearson's correlation coefficient or spearman's rank test. Bivariate logistic regression model will be used to analyse probabilities of medications such as estrogen and anti-androgens as dependent variables, tested for outcome variables such as Ferriman-Galway scale and DLQI. International Business Machines Corporation (IBM), Statistical Package for the Social Sciences (SPSS) software will be used for statistics. A p-value less ≤ 0.05 is considered statistically significant.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hypertrichosis
Hirsutism - Hypertrichosis
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with hypertrichosis
Patients suffering from hypertrichosis or hirsutism according to Ferriman-Galway scale criteria and treated with intense pulse light for a total of 5 sessions.
Intense pulsed light
Intervention Type
OTHER
Already described in the arm/group description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intense pulsed light
Already described in the arm/group description
Intervention Type
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age and above
* Diagnosis of PCOS obtained by a gynaecologist and hirsutism,
* Diagnosis of gender dysphoria obtained after psychiatric evaluation,
* ≥3 points in hair density according to Ferriman-Gallwey scale on a specific part of the body
* Diagnosis of PCOS obtained by a gynaecologist and hirsutism,
* Diagnosis of gender dysphoria obtained after psychiatric evaluation,
* ≥3 points in hair density according to Ferriman-Gallwey scale on a specific part of the body
Exclusion Criteria
* Language barrier causing problem in understanding questionnaires or not being able to give consent
* Hair colours of white, orange or grey hair
* Skin type 5 and above according to Fitzpatrick
* Hereditary hypertrichosis
* Hair colours of white, orange or grey hair
* Skin type 5 and above according to Fitzpatrick
* Hereditary hypertrichosis
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alexander Shayesteh
OTHER_GOV
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Alexander Shayesteh
Assistant professor and senior consultant
Responsibility Role
SPONSOR_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Åsa Nordlund, Chief
Role: STUDY_DIRECTOR
Region Västerbotten
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Norrlands University Hospital
Umeå, Västerbotten County, Sweden
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Sweden
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Park AM, Khan S, Rawnsley J. Hair Biology: Growth and Pigmentation. Facial Plast Surg Clin North Am. 2018 Nov;26(4):415-424. doi: 10.1016/j.fsc.2018.06.003. Epub 2018 Aug 16.
Reference Type
BACKGROUND
Mimoto MS, Oyler JL, Davis AM. Evaluation and Treatment of Hirsutism in Premenopausal Women. JAMA. 2018 Apr 17;319(15):1613-1614. doi: 10.1001/jama.2018.2611.
Reference Type
BACKGROUND
Saleh D, Yarrarapu SNS, Cook C. Hypertrichosis. 2023 Aug 16. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK534854/
Reference Type
BACKGROUND
FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961 Nov;21:1440-7. doi: 10.1210/jcem-21-11-1440. No abstract available.
Reference Type
BACKGROUND
DeUgarte CM, Woods KS, Bartolucci AA, Azziz R. Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism. J Clin Endocrinol Metab. 2006 Apr;91(4):1345-50. doi: 10.1210/jc.2004-2301. Epub 2006 Jan 31.
Reference Type
BACKGROUND
Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012 Mar-Apr;18(2):146-70. doi: 10.1093/humupd/dmr042. Epub 2011 Nov 6.
Reference Type
BACKGROUND
Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C. Clinical diagnosis of hirsutism in Thai women. J Med Assoc Thai. 2004 May;87(5):459-63.
Reference Type
BACKGROUND
Lindholm A, Andersson L, Eliasson M, Bixo M, Sundstrom-Poromaa I. Prevalence of symptoms associated with polycystic ovary syndrome. Int J Gynaecol Obstet. 2008 Jul;102(1):39-43. doi: 10.1016/j.ijgo.2008.01.023. Epub 2008 Mar 5.
Reference Type
BACKGROUND
Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol Endocrinol. 2003 Oct;17(5):379-86. doi: 10.1080/09513590312331290268.
Reference Type
BACKGROUND
Clayton WJ, Lipton M, Elford J, Rustin M, Sherr L. A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome. Br J Dermatol. 2005 May;152(5):986-92. doi: 10.1111/j.1365-2133.2005.06426.x.
Reference Type
BACKGROUND
Meyer G, Boczek U, Bojunga J. Hormonal Gender Reassignment Treatment for Gender Dysphoria. Dtsch Arztebl Int. 2020 Oct 23;117(43):725-732. doi: 10.3238/arztebl.2020.0725.
Reference Type
BACKGROUND
van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N. Interventions for hirsutism (excluding laser and photoepilation therapy alone). Cochrane Database Syst Rev. 2015 Apr 28;2015(4):CD010334. doi: 10.1002/14651858.CD010334.pub2.
Reference Type
BACKGROUND
Babilas P, Schreml S, Szeimies RM, Landthaler M. Intense pulsed light (IPL): a review. Lasers Surg Med. 2010 Feb;42(2):93-104. doi: 10.1002/lsm.20877.
Reference Type
BACKGROUND
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994 May;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-0222-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Treatment of Axillary Hyperhidrosis With Long-pulsed Nd:YAG Laser or IPL
NCT04227691
UNKNOWN
NA
Evaluation of Eflornithine on Facial and Forearm Skin
NCT00152048
COMPLETED
PHASE4
Striae Distensae Treatment Using Deep Skin Abrasion
NCT07087405
NOT_YET_RECRUITING
NA
Comparison of a Face Cream Plus a Laser Procedure and Face Cream Alone in Treatment of Excessive Face Hairs in Female
NCT06976424
RECRUITING
PHASE4
Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism
NCT01817894
COMPLETED
PHASE4
Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities
NCT05359419
UNKNOWN
PHASE4
Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema
NCT05300542
COMPLETED
NA
The Efficacy of Pulsed Dye Laser in Dermatophytosis
NCT00351897
COMPLETED
PHASE1
Treatment of Photodamaged Skin of the décolleté
NCT03573076
TERMINATED
PHASE4
Cryotherapy in Combination with Red Light PDT for Actinic Keratosis of Full Face
NCT06745999
RECRUITING
PHASE4
A Study to Determine the Safety and Efficacy of an Ultrasound Device in the Management of Acute Acne Lesions
NCT01160757
COMPLETED
PHASE1
A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma
NCT03049059
COMPLETED
PHASE2
Efficacy of Combined 1927nm Thulium Fiber Laser and Supramolecular Salicylic Acid in Photoaging Treatment
NCT06925035
COMPLETED
NA
Study of Light Treatment and Laser Treatment for Melasma
NCT00509977
COMPLETED
NA
Control of Hidradenitis Suppurativa of the Underarms After Combination Deroofing and Laser
NCT05484674
UNKNOWN
NA
Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome
NCT01917539
WITHDRAWN
NA
Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
NCT01956435
COMPLETED
NA
Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers
NCT01830764
COMPLETED
PHASE1
CLINICAL INVESTIGATION TO EVALUATE THE EFFICACY AND SAFETY OF EPILADY PROTOTYPE DEVICE FOLLOWED BY APPLICATION OF A TOPICAL FORMULA ON DEPIGMENTATION OF LENTIGO SPOTS
NCT07239726
NOT_YET_RECRUITING
NA
Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma
NCT02095756
COMPLETED
NA
Treatment w/ Tri-Luma® Cream & Intense Pulsed Light (IPL) vs a Mild Inactive Control Cream & Intense Pulsed Light (IPL) in Melasma
NCT00669071
TERMINATED
PHASE4
Evaluation of Safety and Efficacy of IPL Presets for Cutaneous Lesions
NCT05630690
RECRUITING
NA
Long-pulsed 1064 nm Nd-YAG Laser Versus TCA 20% in Treatment of Keratosis Pilaris
NCT04797663
COMPLETED
PHASE4
Efficacy of Laser Hair Removal Therapy in HS
NCT05762484
NOT_YET_RECRUITING
NA